Top Doc: New Heart Drug All About Corporate Profits

Tuesday, 07 May 2013 09:25 AM

By Charlotte Libov

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
 
Amid a hail of publicity, pharmaceutical giant Merck received FDA approval last week for a new cholesterol-lowering drug. But a top cardiologist says he won’t be recommending it to his patients.
 
Liptruzet appears to be all about generating profits for Merck, but it doesn’t seem to add much to the arsenal of weapons in the fight against heart disease, says Chauncey Crandall, M.D.
 
“This is another smokescreen for the drug companies to make money for duplicating another drug,” says Dr. Crandall, head of preventive medicine and cardiology services at the world-renowned Palm Beach Cardiovascular Clinic.
 
Liptruzet doesn’t have any new ingredients. It is a combination of Merck’s existing medication, Zetia, combined with a generic version of Lipitor, the best-selling statin from Pfizer that is no longer patent protected. Liptruzet is expected to become available later this year.
 
“Lipitor went off patent so the drug companies are trying to cash in,” said Dr. Crandall. “This drug does lower cholesterol, but not by a mechanism that reduces risk of heart disease.
 
“Too often drugs are approved that benefit the drug companies, and not the patients.”
 
Research on the combination drug did show that it reduces LDL-cholesterol, the so-called “bad” cholesterol, but the new drug has not been shown to actually lower heart disease or stroke. Liptruzet will be patent-protected, which means Merck will be able to charge more for it than a generic drug.
The new formula comes at a time when Merck has been fighting low sales for its other cholesterol medications. Sales for Zetia and Vytorin (a combination of Zetia and the statin drug Zocor) have not recovered since falling in 2008. That’s when a major study found that they did not stem the progression of heart disease in people with familial hyperlipidemia, an inherited condition in which the body manufactures too much cholesterol.
 
The FDA’s approval last week of Liptruzet came as a surprise because experts expected regulators to wait until a major clinical trial assessing Vytorin, another combo cholesterol drug, is concluded at the end of 2014. However, an FDA spokeswoman said the Liptruzet was approved because it is effective in lowering LDL-cholesterol, which is a known heart disease risk factor.
 
“I prescribed Zetia early on until the studies showed that it was not an effective medication to lower heart disease, and then I switched. So I have no intention of recommending this new combination drug, and I doubt many of my colleagues will either,” Dr. Crandall said.

 

© 2014 Newsmax. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Israel's 'Iron Dome' Makers Hit by Hackers

Tuesday, 29 Jul 2014 18:42 PM

Three Israeli defense contractors behind the Iron Dome missile shield and related systems were robbed of hundreds of doc . . .

Israel Intensifies Gaza Assault, Egyptians Revise Truce Plan

Tuesday, 29 Jul 2014 15:03 PM

Israel knocked out Gaza's only power plant and pounded dozens of other high-profile targets on Tuesday, while Egyptian m . . .

Lawmakers Try to Seal $225M Aid Package for Israel

Tuesday, 29 Jul 2014 13:40 PM

Democratic and Republican members of Congress scrambled Tuesday to seal a $225 million boost to Israel's Iron Dome missi . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved